10.1161/STROKEAHA.114.005427 Stroke 79 HelmsH
Here is where the conversation gets critical, and where many people unknowingly put themselves at risk
Amgen is exploring novel biologics and peptide-based therapies, including GLP-1 receptor agonists, aiming to expand treatment options for obesity and diabetes
For many people living with overweight or obesity, GLP-1s have been transformative helping them lose weight and achieve a level of health that once felt impossible
The demonstrated activity of PYC against viruses, such as HCV, DENV, and SARS-CoV-2, highlights its broad-spectrum therapeutic potential
Hepatokines as diagnostic biomarkers The diagnosis of AD remains a multifaceted challenge, requiring comprehensive assessments that combine patient history, neuroimaging, biomarker evaluation, and risk factor analysis [261]